A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Shanghai Allink Biotherapeutics Co., Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cancer Commons
Weill Medical College of Cornell University
Singapore General Hospital
University of Colorado, Denver
Canadian Cancer Trials Group
University of Rochester
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bristol-Myers Squibb
Duke University
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Suzhou Transcenta Therapeutics Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bristol-Myers Squibb
Agenus Inc.
Bristol-Myers Squibb
Prescient Therapeutics, Ltd.
Anwita Biosciences
ElmediX
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University Health Network, Toronto
HC Biopharma Inc.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Memorial Sloan Kettering Cancer Center
ImmuneOncia Therapeutics Inc.
National Taiwan University Hospital
Weill Medical College of Cornell University
University of Colorado, Denver
Bristol-Myers Squibb
Shanghai Allink Biotherapeutics Co., Ltd.
Mayo Clinic
Akeso
Institut du Cancer de Montpellier - Val d'Aurelle
Duke-NUS Graduate Medical School
Dana-Farber Cancer Institute
Massachusetts General Hospital
Gustave Roussy, Cancer Campus, Grand Paris
Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Eli Lilly and Company
University of Colorado, Denver
iTeos Therapeutics
Bien-Willner Physicians Group PA
University of Iowa
Qinghai Red Cross Hospital